Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

Apr 14, 2022

SELL
$7.65 - $15.29 $26,010 - $51,986
-3,400 Reduced 58.62%
2,400 $0
Q4 2021

Jan 18, 2022

BUY
$13.13 - $24.52 $76,154 - $142,216
5,800 New
5,800 $1,000
Q4 2020

Jan 21, 2021

SELL
$25.24 - $43.45 $65,624 - $112,970
-2,600 Closed
0 $0
Q3 2020

Oct 27, 2020

BUY
$32.38 - $44.96 $3,238 - $4,496
100 Added 4.0%
2,600 $12,000
Q2 2020

Jul 22, 2020

BUY
$18.39 - $54.04 $45,975 - $135,100
2,500 New
2,500 $32,000
Q1 2020

May 07, 2020

SELL
$18.22 - $28.25 $1,822 - $2,825
-100 Closed
0 $0
Q4 2019

Feb 06, 2020

SELL
$24.82 - $31.4 $67,014 - $84,780
-2,700 Reduced 96.43%
100 $0
Q3 2019

Oct 28, 2019

BUY
$26.11 - $32.99 $65,275 - $82,475
2,500 Added 833.33%
2,800 $4,000
Q2 2019

Aug 09, 2019

BUY
$25.56 - $31.09 $7,668 - $9,327
300 New
300 $0

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $292M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.